Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study.

Muramatsu T, Matsushita K, Yamashita K, Kondo T, Maeda K, Shintani S, Ichimiya S, Ohno M, Sone T, Ikeda N, Watarai M, Murohara T; NAGOYA HEART Study Investigators.

Hypertension. 2012 Mar;59(3):580-6. doi: 10.1161/HYPERTENSIONAHA.111.184226. Epub 2012 Jan 9. Erratum in: Hypertension. 2015 Jul;66(1):e1.

4.

Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance.

Matsushita K, Muramatsu T, Kondo T, Maeda K, Shintani S, Murohara T; NAGOYA HEART Study Group.

J Cardiol. 2010 Jul;56(1):111-7. doi: 10.1016/j.jjcc.2010.03.004. Epub 2010 Apr 20. Erratum in: J Cardiol. 2015 Mar;65(3):259.

5.

Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease.

Yamashita K, Kondo T, Muramatsu T, Matsushita K, Nagahiro T, Maeda K, Shintani S, Murohara T.

Am J Cardiol. 2013 Dec 1;112(11):1750-6. doi: 10.1016/j.amjcard.2013.07.043. Epub 2013 Sep 13.

PMID:
24035165
6.

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group.

Lancet. 2004 Jun 19;363(9426):2022-31.

PMID:
15207952
7.

Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.

Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M, Laragh JH, Plat F, Battegay E, Calvo-Vargas C, Cieśliński A, Degaute JP, Holwerda NJ, Kobalava J, Pedersen OL, Rudyatmoko FP, Siamopoulos KC, Störset O.

J Hypertens. 2006 Nov;24(11):2163-8.

PMID:
17053536
8.

Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial.

Narumi H, Takano H, Shindo S, Fujita M, Mizuma H, Kuwabara Y, Komuro I; Valsartan Amlodipine Randomized Trial Investigators.

Hypertens Res. 2011 Jan;34(1):62-9. doi: 10.1038/hr.2010.186. Epub 2010 Oct 7. Erratum in: Hypertens Res. 2013 Jul;36(7):655. Hypertens Res. 2011 Jan;34(1):152. Retraction in: Hypertens Res. 2017 Jan;40(1):103.

PMID:
20927112
9.

Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART.

Takano H, Hasegawa H, Narumi H, Shindo S, Mizuma H, Kuwabara Y, Kobayashi Y, Komuro I; VART investigators.

J Hum Hypertens. 2012 Nov;26(11):656-63. doi: 10.1038/jhh.2011.91. Epub 2011 Oct 13. Erratum in: J Hum Hypertens. 2013 Sep;27(9):580. Retraction in: J Hum Hypertens. 2015 May;29(5):337.

PMID:
21993491
11.

Valsartan Amlodipine Randomized Trial (VART): design, methods, and preliminary results.

Nakayama K, Kuwabara Y, Daimon M, Shindo S, Fujita M, Narumi H, Mizuma H, Komuro I.

Hypertens Res. 2008 Jan;31(1):21-8. doi: 10.1291/hypres.31.21.

PMID:
18360014
12.

Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial.

Kjeldsen SE, McInnes GT, Mancia G, Hua TA, Julius S, Weber MA, Coca A, Girerd X, Jamerson K, Larochelle P, Macdonald T, Schmieder RE, Anthony Schork M, Viskoper R, Widimsky J, Zanchetti A.

Blood Press. 2008;17(3):170-7. doi: 10.1080/08037050802169644.

PMID:
18608200
13.

Effect of valsartan on the incidence of diabetes and cardiovascular events.

NAVIGATOR Study Group, McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár J, Califf RM.

N Engl J Med. 2010 Apr 22;362(16):1477-90. doi: 10.1056/NEJMoa1001121. Epub 2010 Mar 14. Erratum in: N Engl J Med. 2010 May 6;362(18):1748.

14.

Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.

Kjeldsen SE, Julius S, Mancia G, McInnes GT, Hua T, Weber MA, Coca A, Ekman S, Girerd X, Jamerson K, Larochelle P, MacDonald TM, Schmieder RE, Schork MA, Stolt P, Viskoper R, Widimský J, Zanchetti A; VALUE Trial Investigators.

J Hypertens. 2006 Jul;24(7):1405-12.

PMID:
16794491
15.

The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy.

Julius S, Weber MA, Kjeldsen SE, McInnes GT, Zanchetti A, Brunner HR, Laragh J, Schork MA, Hua TA, Amerena J, Balazovjech I, Cassel G, Herczeg B, Koylan N, Magometschnigg D, Majahalme S, Martinez F, Oigman W, Seabra Gomes R, Zhu JR.

Hypertension. 2006 Sep;48(3):385-91. Epub 2006 Jul 24.

16.

Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.

Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T; Candesartan Antihypertensive Survival Evaluation in Japan Trial Group.

Hypertension. 2008 Feb;51(2):393-8. doi: 10.1161/HYPERTENSIONAHA.107.098475. Epub 2008 Jan 2.

17.

Comparative effects of telmisartan and valsartan as add-on agents for hypertensive patients with morning blood pressure insufficiently controlled by amlodipine monotherapy.

Yoshida H, Akasaka H, Saitoh S, Shimamoto K, Miura T; SPEED investigators.

Hypertens Res. 2014 Mar;37(3):225-31. doi: 10.1038/hr.2013.141. Epub 2013 Oct 10.

PMID:
24108237
18.

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.

Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators.

Circulation. 2002 Aug 6;106(6):672-8.

19.

Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.

Ogawa H, Kim-Mitsuyama S, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K; OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Group.

Am J Med. 2012 Oct;125(10):981-90. doi: 10.1016/j.amjmed.2011.12.010. Epub 2012 Apr 14.

PMID:
22503610

Supplemental Content

Support Center